Ownership history in MARSHALL WACE, LLP Β· 18 quarters on record
This page tracks every 13F SEC filing in which MARSHALL WACE, LLP reported a position in RHYTHM PHARMACEU (RYTM). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π MARSHALL WACE, LLP outperformed the S&P 500 by +22.7% annually on this RYTM position. Timing score: 47% (8/17 decisions correct). Average cost basis: $43.31. Maximum drawdown during holding period: β44.5%.
π₯ Exceptional β beat the S&P 500 by 22.7% per year on this position.
17 quarters analyzed
β‘οΈ Neutral timing β roughly coin-flip accuracy on add/trim calls.
8 of 17 add/trim decisions correct
Best entry: $17.84 (2023 Q1) Β· Worst: $55.98 (2024 Q4)
πͺ Held through 3 major drawdowns (>20%). Diamond-hands conviction.
9 adds Β· 9 trims. Bought during 4 of 7 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.02% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size